Arcturus Therapeutics to Attend the Following Investor Conferences
02 September 2022 - 6:00AM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a global, late-stage messenger RNA medicines company
focused on the development of infectious disease vaccines and
significant opportunities within liver and respiratory rare
diseases, today announced that the Company will participate in the
following investor conferences.
Citi’s 17th Annual BioPharma Conference (Attending)
- Tuesday – Thursday, September 6 – 8, 2022
Wells Fargo Virtual Healthcare Conference (Fireside
Chat)
- Friday, September 9, 2022 (8:35 a.m. ET)
H.C. Wainwright 24th Annual Global Investment Conference
(Presentation)
- Monday, September 12, 2022 (3:00 p.m. ET)
Baird Global Healthcare Conference (Presentation)
- Wednesday, September 14, 2022 (10:15 a.m. ET)
Cantor Global Healthcare Conference (Panel
Presentation)
- Thursday, September 15, 2022 (2:30 p.m. ET)
Piper Sandler Heartland Summit (Attending)
- Wednesday – Thursday, September 21 – 22, 2022
Links will be available under the Investor Relations/Events
section of Arcturus’ website.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global, late-stage
clinical mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA
Technology (samRNA) and (iii) mRNA drug substance along with drug
product manufacturing expertise. Arcturus’ diverse pipeline of RNA
therapeutic and vaccine candidates includes mRNA vaccine programs
for SARS-CoV-2 (COVID-19) and Influenza, and other programs to
potentially treat ornithine transcarbamylase (OTC) deficiency, and
cystic fibrosis, along with partnered programs including glycogen
storage disease type III, and hepatitis B virus. Arcturus’
versatile RNA therapeutics platforms can be applied toward multiple
types of nucleic acid medicines including messenger RNA, small
interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and
gene editing therapeutics. Arcturus’ technologies are covered by
its extensive patent portfolio (patents and patent applications
issued in the U.S., Europe, Japan, China and other countries).
Arcturus’ commitment to the development of novel RNA therapeutics
has led to collaborations including, amongst others, Janssen
Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies
of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the
Cystic Fibrosis Foundation. In addition, please connect with us on
Twitter and LinkedIn. For more information visit
www.ArcturusRx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220901005815/en/
IR and Media Contacts Arcturus Therapeutics
IR@arcturusrx.com
Kendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008
ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Apr 2023 to Apr 2024